Bacterial co- or superinfection in patients treated in intensive care unit with COVID-19- and influenza-associated pneumonia

• Verfasst von: Schöttler, Jochen [VerfasserIn]
• Verfasst von: Sandrio, Stany [VerfasserIn]
• Verfasst von: Bösing, Christoph [VerfasserIn]
• Verfasst von: Bauer, Lena [VerfasserIn]
• Verfasst von: Miethke, Thomas [VerfasserIn]
• Verfasst von: Thiel, Manfred [VerfasserIn]
• Verfasst von: Krebs, Jörg [VerfasserIn]
• Titel: Bacterial co- or superinfection in patients treated in intensive care unit with COVID-19- and influenza-associated pneumonia
• Verf.angabe: Jochen Johannes Schoettler, Stany Sandrio, Christoph Boesing, Lena Bauer, Thomas Miethke, Manfred Thiel, and Joerg Krebs
• E-Jahr: 2023
• Jahr: 10 May 2023
• Umfang: 13 S.
• Illustrationen: Illustrationen
• Fussnoten: Gesehen am 07.08.2024
• Titel Quelle: Enthalten in: Pathogens
• Ort Quelle: Basel : MDPI, 2012
• Jahr Quelle: 2023
• Band/Heft Quelle: 12(2023), 7, Artikel-ID 927, Seite 1-13
• ISSN Quelle: 2076-0817
• DOI: doi:10.3390/pathogens12070927
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: acute respiratory distress syndrome
• Sach-SW: bacterial co- or superinfection
• Sach-SW: COVID-19
• Sach-SW: influenza
• Sach-SW: pneumonia
• Sach-SW: SARS-CoV-2
• K10plus-PPN: 1898046158

Abstract

Viral pneumonia is frequently complicated by bacterial co- or superinfection (c/s) with adverse effects on patients’ outcomes. However, the incidence of c/s and its impact on the outcomes of patients might be dependent on the type of viral pneumonia. We performed a retrospective observational study in patients with confirmed COVID-19 pneumonia (CP) or influenza pneumonia (IP) from 01/2009 to 04/2022, investigating the incidence of c/s using a competing risk model and its impact on mortality in these patients in a tertiary referral center using multivariate logistic regressions. Co-infection was defined as pulmonary pathogenic bacteria confirmed in tracheal aspirate or bronchoalveolar lavage within 48 h after hospitalization. Superinfection was defined as pulmonary pathogenic bacteria detected in tracheal aspirate or bronchoalveolar lavage 48 h after hospitalization. We examined 114 patients with CP and 76 patients with IP. Pulmonary bacterial co-infection was detected in 15 (13.2%), and superinfection was detected in 50 (43.9%) of CP patients. A total of 5 (6.6%) co-infections (p = 0.2269) and 28 (36.8%) superinfections (p = 0.3687) were detected in IP patients. The overall incidence of c/s did not differ between CP and IP patients, and c/s was not an independent predictor for mortality in a study cohort with a high disease severity. We found a significantly higher probability of superinfection for patients with CP compared to patients with IP (p = 0.0017).